Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis

Xiao-Lan Ruan,Sheng Li,Peiliang Geng,Xian-Tao Zeng,Guo-Zheng Yu,Xiang-Yu Meng,Qing-Ping Gao,Xu-Bin Ao
DOI: https://doi.org/10.12659/msm.894625
2015-01-01
Medical Science Monitor
Abstract:Background: Many studies have reported that the p53 codon 72 polymorphism is associated with acute myeloid leukemia (AML) susceptibility; however, the conclusions are inconsistent. Therefore, we performed this meta-analysis to obtain a more precise result.Material/Methods: We searched PubMed to identify relevant studies, and 6 published case-control studies were retrieved, including 924 AML patients and 3832 controls. Odds ratio (OR) with corresponding 95% confidence interval (95% CI) was applied to assess the association between p53 codon 72 polymorphism and AML susceptibility. The meta-analysis was performed with Comprehensive Meta-Analysis software, version 2.2.Results: Overall, no significant association between p53 codon 72 polymorphism and AML susceptibility was found in this meta-analysis (Pro vs. Arg: OR=0.94, 95% CI=0.81-1.10; Pro/Pro vs. Arg/Arg: OR=0.93, 95% CI=0.71-1.22; Arg/Pro vs. Arg/Arg: OR=0.79, 95% CI=0.55-1.13; (Pro/Pro + Arg/Pro) vs. Arg/Arg: OR=0.84, 95% CI=0.62-1.13; Pro/Pro vs. (Arg/Arg + Arg/Pro): OR=1.06, 95% CI=0.83-1.35). Similar results were also found in stratified analysis according to ethnicity and source of controls.Conclusions: Our meta-analysis demonstrates that p53 codon 72 polymorphism may not be a risk factor for AML, which should be verified in future studies.
What problem does this paper attempt to address?